TRUNCATE-TB: an innovative trial design for drug-sensitive tuberculosis | Zendy

Padmasayee Papineni | Zendy; Patrick Phillips | Zendy; Qingshu Lu | Zendy; YB Cheung | Zendy; Andrew Nunn | Zendy; Nicholas I. Paton | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

TRUNCATE-TB: an innovative trial design for drug-sensitive tuberculosis

Author(s) -

Padmasayee Papineni,

Patrick Phillips,

Qingshu Lu,

YB Cheung,

Andrew Nunn,

Nicholas I. Paton

Publication year - 2016

Publication title -

international journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.278

H-Index - 89

eISSN - 1878-3511

pISSN - 1201-9712

DOI - 10.1016/j.ijid.2016.02.863

Subject(s) - medicine , rifapentine , bedaquiline , clofazimine , tuberculosis , interim analysis , moxifloxacin , clinical trial , intensive care medicine , antibiotics , mycobacterium tuberculosis , pathology , leprosy , microbiology and biotechnology , dermatology , latent tuberculosis , biology

Background: The number of potential regimens of drug treatment for TB is vast, meaning that evaluating each new treatment against a control in separate two-arm trials requires a huge amount of resources. There is, therefore, a need for innovative trial designs that can evaluate drug regimens simultaneously.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research